[HTML][HTML] A comparison between angiotensin converting enzyme inhibitors and angiotensin receptor blockers on end stage renal disease and major adverse …
LS Wu, SH Chang, GJ Chang, JR Liu, YH Chan… - Cardiovascular …, 2016 - Springer
Background Contemporary guidelines recommend angiotensin-converting-enzyme
inhibitors (ACEi) or angiotensin-receptor blockers (ARB) for hypertensive patients with …
inhibitors (ACEi) or angiotensin-receptor blockers (ARB) for hypertensive patients with …
[HTML][HTML] Comparative effectiveness of angiotensin-converting enzyme inhibitors versus angiotensin II receptor blockers for major renal outcomes in patients with …
Background Angiotensin converting enzyme inhibitors (ACEIs) and angiotensin II receptor
blockers (ARBs) are considered to have similar renoprotective effects; so far there has been …
blockers (ARBs) are considered to have similar renoprotective effects; so far there has been …
Angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers for end-stage renal disease/mortality in type 2 diabetes
HM Campbell, N Khan, DW Raisch, ME Borrego… - Diabetes Research and …, 2013 - Elsevier
Aims To compare angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin
receptor blockers (ARBs) for end-stage renal disease (ESRD) development and all-cause …
receptor blockers (ARBs) for end-stage renal disease (ESRD) development and all-cause …
Effects of renin–angiotensin system blockers on renal outcomes and all-cause mortality in patients with diabetic nephropathy: an updated meta-analysis
PA Sarafidis, PC Stafylas, AI Kanaki… - American journal of …, 2008 - academic.oup.com
Background In contrast to previous studies, recent data questioned the ability of renin–
angiotensin–aldosterone system (RAAS) blockers to delay progression of diabetic …
angiotensin–aldosterone system (RAAS) blockers to delay progression of diabetic …
Effects of renin–angiotensin system blockers on renal and cardiovascular outcomes in patients with diabetic nephropathy: a meta-analysis of randomized controlled …
X Liu, L Ma, Z Li - Journal of Endocrinological Investigation, 2020 - Springer
Purpose This study aimed to evaluate the effect f angiotensin-converting enzyme inhibitors
(ACEI) and angiotensin receptor blockers (ARB) on renal or cardiovascular outcomes in …
(ACEI) and angiotensin receptor blockers (ARB) on renal or cardiovascular outcomes in …
Angiotensin-converting enzyme inhibitors reduce albuminuria more than angiotensin receptor blockers in patients with type 2 diabetes
NA Al-Sayed, T Gao, BJ Wells, C Yu, RS Zimmerman - Endocrine Practice, 2013 - Elsevier
Objective This study retrospectively compared the effects of angiotensin-converting enzyme
inhibitors (ACEIs) versus angiotensin receptor blockers (ARBs) as classes with respect to …
inhibitors (ACEIs) versus angiotensin receptor blockers (ARBs) as classes with respect to …
Comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on major adverse cardiac events in patients with newly …
CJ Shih, H Chu, SM Ou, YT Chen - International Journal of Cardiology, 2015 - Elsevier
Background Guidelines for hypertension management recommend either angiotensin-
converting enzyme inhibitors (ACEIs) or angiotensin II receptor blockers (ARBs) as first-line …
converting enzyme inhibitors (ACEIs) or angiotensin II receptor blockers (ARBs) as first-line …
Comparative efficacy of individual renin–angiotensin system inhibitors on major renal outcomes in diabetic kidney disease: a network meta-analysis
J Cai, X Huang, Z Zheng, Q Lin… - Nephrology Dialysis …, 2018 - academic.oup.com
Background Angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor
blockers (ARBs) are two drug classes with well-documented renal protective effects …
blockers (ARBs) are two drug classes with well-documented renal protective effects …
Therapeutic controversies in hypertension management: angiotensin converting enzyme (ACE) inhibitors or angiotensin receptor blockers in diabetic nephropathy …
ED Crook, S Penumalee - Ethnicity & Disease, 2004 - europepmc.org
Diabetic nephropathy is the number one cause of endstage renal disease in the United
States. Blood pressure is most important in delaying the progression of renal disease in …
States. Blood pressure is most important in delaying the progression of renal disease in …
ACEI and ARB Lower the Incidence of End‐Stage Renal Disease among Patients with Diabetic Nephropathy: A Meta‐analysis
X Deng, D Li, Q Tang, Y Chen - … and Mathematical Methods in …, 2022 - Wiley Online Library
Objective. This study explores the effects of Angiotensin‐Converting Enzyme Inhibitors
(ACEI) or Angiotensin Receptor Blockers (ARB) on the incidence of end‐stage renal disease …
(ACEI) or Angiotensin Receptor Blockers (ARB) on the incidence of end‐stage renal disease …